EE200200251A - Uued N-asabitsükloamiidi derivaadid ja nende kasutamine - Google Patents

Uued N-asabitsükloamiidi derivaadid ja nende kasutamine

Info

Publication number
EE200200251A
EE200200251A EEP200200251A EEP200200251A EE200200251A EE 200200251 A EE200200251 A EE 200200251A EE P200200251 A EEP200200251 A EE P200200251A EE P200200251 A EEP200200251 A EE P200200251A EE 200200251 A EE200200251 A EE 200200251A
Authority
EE
Estonia
Prior art keywords
azabicycloamide
derivatives
novel
azabicycloamide derivatives
Prior art date
Application number
EEP200200251A
Other languages
English (en)
Estonian (et)
Inventor
Balestra Michael
Mullen George
Phillips Eifion
Schmiesing Richard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200251A publication Critical patent/EE200200251A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
EEP200200251A 1999-11-18 2000-11-16 Uued N-asabitsükloamiidi derivaadid ja nende kasutamine EE200200251A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904176A SE9904176D0 (sv) 1999-11-18 1999-11-18 New use
PCT/SE2000/002262 WO2001036417A1 (en) 1999-11-18 2000-11-16 New use and novel n-azabicyclo-amide derivatives

Publications (1)

Publication Number Publication Date
EE200200251A true EE200200251A (et) 2003-06-16

Family

ID=20417766

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200251A EE200200251A (et) 1999-11-18 2000-11-16 Uued N-asabitsükloamiidi derivaadid ja nende kasutamine

Country Status (31)

Country Link
US (1) US6683090B1 (sv)
EP (1) EP1233964B1 (sv)
JP (1) JP2003514818A (sv)
KR (1) KR20020058014A (sv)
CN (1) CN1217943C (sv)
AR (1) AR031680A1 (sv)
AT (1) ATE298337T1 (sv)
AU (1) AU784400B2 (sv)
BG (1) BG106680A (sv)
BR (1) BR0015624A (sv)
CA (1) CA2389604A1 (sv)
CO (1) CO5261607A1 (sv)
CZ (1) CZ20021692A3 (sv)
DE (1) DE60020994T2 (sv)
DK (1) DK1233964T3 (sv)
EE (1) EE200200251A (sv)
ES (1) ES2242653T3 (sv)
HK (1) HK1047743A1 (sv)
HU (1) HUP0204245A3 (sv)
IL (1) IL149374A0 (sv)
IS (1) IS6385A (sv)
MX (1) MXPA02004911A (sv)
NO (1) NO20022289L (sv)
NZ (1) NZ518571A (sv)
PL (1) PL355867A1 (sv)
PT (1) PT1233964E (sv)
SE (1) SE9904176D0 (sv)
SK (1) SK6772002A3 (sv)
UA (1) UA74172C2 (sv)
WO (1) WO2001036417A1 (sv)
ZA (1) ZA200203316B (sv)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1381603A2 (en) * 2000-08-18 2004-01-21 PHARMACIA &amp; UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
AU2001282873A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001284645A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282910A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AU2002320958B2 (en) * 2001-07-06 2008-02-28 Neurosearch A/S Novel compounds, their preparation and use
CA2458375A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
CA2462453C (en) * 2001-10-02 2009-07-28 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
CA2464194A1 (en) * 2001-10-26 2003-05-08 Pharmacia & Upjohn Company N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
EP1442041A1 (en) * 2001-11-08 2004-08-04 PHARMACIA &amp; UPJOHN COMPANY Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
BR0214016A (pt) 2001-11-09 2004-10-13 Upjohn Co Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr
CA2470567A1 (en) 2001-12-14 2003-06-26 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2003070728A2 (en) 2002-02-15 2003-08-28 Pharmacia & Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
JP2005523288A (ja) * 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
CA2476624A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
MXPA04011858A (es) 2002-05-30 2005-03-31 Neurosearch As Quinuclidinas sustituidas en la posicion 3 y su uso.
AU2003253686A1 (en) 2002-08-01 2004-02-23 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
EP2298758A1 (en) 2002-08-30 2011-03-23 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegenerative diseases
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
HUP0500610A3 (en) 2002-09-25 2013-12-30 Memory Pharm Corp Indazoles, benzothiazoles, and benzoisothiazoles, pharmaceutical compositions comprises thereof and their uses
BR0317110A (pt) * 2002-12-11 2005-10-25 Pharmacia & Upjohn Co Llc Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
DE602004024565D1 (de) 2003-10-15 2010-01-21 Targacept Inc Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
CA2560741C (en) 2004-03-25 2013-08-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1917265B1 (en) 2005-08-22 2010-09-29 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
JP5109132B2 (ja) * 2005-09-28 2012-12-26 国立大学法人 熊本大学 注意欠陥・多動性障害の治療薬
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US9233106B2 (en) * 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
ATE503754T1 (de) 2007-10-01 2011-04-15 Comentis Inc 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
ES2430622T3 (es) 2008-02-13 2013-11-21 Targacept, Inc. Combinación de agonistas nicotínicos alfa 7 y antipsicóticos
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
RU2577334C2 (ru) 2010-05-17 2016-03-20 Энвиво Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ ФОРМА МОНОГИДРАТА ГИДРОХЛОРИДА (R)-7-ХЛОР-N-(ХИНУКЛИДИН-3-ИЛ)БЕНЗО[b]ТИОФЕН-2-КАРБОКСАМИДА
FR2974365B1 (fr) * 2011-04-20 2017-08-25 Centre Nat De La Rech Scient (C N R S) 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques
WO2012177856A2 (en) * 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
EP2953940B1 (en) 2013-02-07 2018-08-22 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists
EP3010900B1 (en) 2013-06-21 2018-01-03 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
EP3166940A4 (en) 2014-07-11 2018-04-25 Alpharmagen, LLC Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255467B (it) * 1992-07-29 1995-11-02 Dompe Farmaceutici Spa Ammidi acriliche farmacologicamente attive
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
CA2209936A1 (en) * 1995-01-10 1996-07-18 Smithkline Beecham S.P.A. Indole derivatives useful in the treatment of osteoporosis

Also Published As

Publication number Publication date
ATE298337T1 (de) 2005-07-15
SE9904176D0 (sv) 1999-11-18
PL355867A1 (en) 2004-05-31
HUP0204245A3 (en) 2004-12-28
CA2389604A1 (en) 2001-05-25
KR20020058014A (ko) 2002-07-12
BG106680A (bg) 2003-01-31
CN1217943C (zh) 2005-09-07
SK6772002A3 (en) 2002-09-10
IS6385A (is) 2002-05-15
DK1233964T3 (da) 2005-09-19
EP1233964B1 (en) 2005-06-22
NO20022289L (no) 2002-06-24
US6683090B1 (en) 2004-01-27
CN1423651A (zh) 2003-06-11
BR0015624A (pt) 2002-07-30
DE60020994D1 (de) 2005-07-28
ES2242653T3 (es) 2005-11-16
CZ20021692A3 (cs) 2003-01-15
EP1233964A1 (en) 2002-08-28
DE60020994T2 (de) 2006-04-27
ZA200203316B (en) 2004-02-25
JP2003514818A (ja) 2003-04-22
CO5261607A1 (es) 2003-03-31
NZ518571A (en) 2004-05-28
AU784400B2 (en) 2006-03-23
HK1047743A1 (en) 2003-03-07
NO20022289D0 (no) 2002-05-14
AU1907301A (en) 2001-05-30
AR031680A1 (es) 2003-10-01
IL149374A0 (en) 2002-11-10
PT1233964E (pt) 2005-09-30
UA74172C2 (uk) 2005-11-15
MXPA02004911A (es) 2002-09-18
WO2001036417A1 (en) 2001-05-25
HUP0204245A2 (hu) 2003-03-28

Similar Documents

Publication Publication Date Title
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE05169B1 (et) Asendatud oksasolidinoonid ja nende kasutamine
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
EE200200175A (et) Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
ID26056A (id) Popok sekali pakai
ID26389A (id) Popok sekali pakai
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
FI20000677A (sv) Oximderivat och deras användning som latenta syror
NO20000885D0 (no) 4-Fenyl-pyridin-derivater
DE60009747D1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
EE200100613A (et) 13-metüülerütromütsiini derivaadid
EE04497B1 (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
ATE257148T1 (de) Propargyletherderivate
PT1246816E (pt) Derivados de fenilpiperazina substituidos sua preparacao e utilizacao
PT1237856E (pt) Novos derivados fenilicos tri-substituidos e analogos
ID24782A (id) Popok sekali pakai
ID25571A (id) Popok sekali pakai
ATE374747T1 (de) Monofluoralkylderivate
DK1154988T3 (da) Mevinolinderivater
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
ATE293592T1 (de) Resorcinderivate
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate